Frédéric Grimaud
President at Grimaud Vietnam Co. Ltd.
Net worth: 1 M $ as of 30/03/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Franck Grimaud | M | 58 |
Chengdu Grimaud Breeding Co. Ltd.
Grimaud Deyang Animal Co. Ltd.
Vivalis SA
 Vivalis SA Pharmaceuticals: OtherHealth Technology Vivalis SA manufactures human and animal vaccines. The firm specializes in the research and development of vaccines and antiviral molecules, as well as in recombinant therapeutic protein and monoclonal antibody expression systems development. The firm's embryonic stem cells are used for practical applications in human and animal health. It also helps its clients in a case by case basis for the development of processes in the frame of service agreement. The company was founded in April 1999 and is headquartered in France.
Intercell Austria AG
| 25 years |
| Thomas Lingelbach | M | 60 |
Intercell Austria AG
| 11 years |
| Alain Munoz | M | 75 |
Vivalis SA
Vivalis SA Pharmaceuticals: OtherHealth Technology Vivalis SA manufactures human and animal vaccines. The firm specializes in the research and development of vaccines and antiviral molecules, as well as in recombinant therapeutic protein and monoclonal antibody expression systems development. The firm's embryonic stem cells are used for practical applications in human and animal health. It also helps its clients in a case by case basis for the development of processes in the frame of service agreement. The company was founded in April 1999 and is headquartered in France.
Intercell Austria AG
| 12 years |
| Anne-Marie Graffin | F | 63 | 11 years | |
| Yann Le Pottier | M | - |
Grimaud Frères Holding SASU
 Grimaud Frères Holding SASU Financial ConglomeratesFinance Grimaud Frères Holding SASU is an investment holding private company based in Sevremoine, France. and has subsidiaries in China. Grimaud Frères Holding SASU functions as an investment holding French company. The company was founded in 2014, and Yann Le Pottier has been the CEO of the company since 2014.
Grimaud Frères Sélection SAS
 Grimaud Frères Sélection SAS Agricultural Commodities/MillingProcess Industries Grimaud Frères Sélection SAS is a poultry firm. Its products include mule, muscovy, pekin ducks, gesse and pigeons. The company was founded in 1995 and is headquartered in Sevremoine, France. | 10 years |
| Jim Connolly | M | 59 | 2 years | |
| Peter Buhler | M | 54 | 3 years | |
| Laetitia Bachelot-Fontaine | F | - | 11 years | |
| James Sulat | M | 73 | 11 years | |
| Frédéric Jacotot | M | 60 | 7 years | |
| Bryce Martin | M | - |
Choice Genetics USA LLC
 Choice Genetics USA LLC BiotechnologyHealth Technology Choice Genetics USA LLC produces swine genetics products. Its products include EXM, P26, CG32 and EBX. The company is headquartered in West Des Moines, IA. | - |
| Vincent Dequenne | M | - | 3 years | |
| Dipal Patel | F | - | 2 years | |
| Carlos Alberto Pineda | M | - |
Blue Genetics Mexico
 Blue Genetics Mexico Miscellaneous Commercial ServicesCommercial Services Blue Genetics Mexico is a Mexican global company that specializes in the selection of shrimp genetics and supplies high-quality shrimp broodstock that is specific pathogen-free (SPF). Blue Genetics Mexico is based in La Paz, Mexico. The private company is a subsidiary of Groupe Grimaud. The CEO of the company is Carlos Alberto Pineda. | - |
| Kathrin Jansen | M | - | 1 years | |
| Juan Carlos Jaramillo | M | 53 | 4 years | |
| Maïlys Ferrère | F | 60 | 2 years | |
| Djedjiga Djadour | M | 52 |
Filavie SAS
 Filavie SAS Pharmaceuticals: MajorHealth Technology Filavie SAS manufactures pharmaceutical products. The private company is based in Roussay, France. | 5 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Majid Mehtali | M | 63 |
Vivalis SA
Vivalis SA Pharmaceuticals: OtherHealth Technology Vivalis SA manufactures human and animal vaccines. The firm specializes in the research and development of vaccines and antiviral molecules, as well as in recombinant therapeutic protein and monoclonal antibody expression systems development. The firm's embryonic stem cells are used for practical applications in human and animal health. It also helps its clients in a case by case basis for the development of processes in the frame of service agreement. The company was founded in April 1999 and is headquartered in France. | 10 years |
| Michel Gréco | M | 80 |
Vivalis SA
Vivalis SA Pharmaceuticals: OtherHealth Technology Vivalis SA manufactures human and animal vaccines. The firm specializes in the research and development of vaccines and antiviral molecules, as well as in recombinant therapeutic protein and monoclonal antibody expression systems development. The firm's embryonic stem cells are used for practical applications in human and animal health. It also helps its clients in a case by case basis for the development of processes in the frame of service agreement. The company was founded in April 1999 and is headquartered in France. | 10 years |
| Ralf Clemens | M | 71 | 3 years | |
| Sandra E. Poole | F | 60 | 3 years | |
| Céline Breda | F | 54 |
Vivalis SA
Vivalis SA Pharmaceuticals: OtherHealth Technology Vivalis SA manufactures human and animal vaccines. The firm specializes in the research and development of vaccines and antiviral molecules, as well as in recombinant therapeutic protein and monoclonal antibody expression systems development. The firm's embryonic stem cells are used for practical applications in human and animal health. It also helps its clients in a case by case basis for the development of processes in the frame of service agreement. The company was founded in April 1999 and is headquartered in France. | 8 years |
| Sharon Tetlow | F | 64 | 3 years | |
| Johanna Willemina Pattenier | M | 64 | 3 years | |
| Alexander Ullrich von Gabain | M | 73 | 7 years | |
| Philippe Rousseau | M | 53 |
Vivalis SA
Vivalis SA Pharmaceuticals: OtherHealth Technology Vivalis SA manufactures human and animal vaccines. The firm specializes in the research and development of vaccines and antiviral molecules, as well as in recombinant therapeutic protein and monoclonal antibody expression systems development. The firm's embryonic stem cells are used for practical applications in human and animal health. It also helps its clients in a case by case basis for the development of processes in the frame of service agreement. The company was founded in April 1999 and is headquartered in France. | 4 years |
| Hans Lennart Rudolf Wigzell | M | 86 | 3 years | |
| Renee Grimaud | F | 84 |
Vivalis SA
Vivalis SA Pharmaceuticals: OtherHealth Technology Vivalis SA manufactures human and animal vaccines. The firm specializes in the research and development of vaccines and antiviral molecules, as well as in recombinant therapeutic protein and monoclonal antibody expression systems development. The firm's embryonic stem cells are used for practical applications in human and animal health. It also helps its clients in a case by case basis for the development of processes in the frame of service agreement. The company was founded in April 1999 and is headquartered in France. | - |
| Perry Denis Celentano | M | - | - | |
| Matthias Hebben | M | - | 5 years | |
| Manfred Tiefenbacher | M | - | - | |
| Wolfgang Bender | M | 70 | 3 years | |
| Louisa Shaw-Marotto | F | 56 | 4 years | |
| Frédéric Legros | M | 48 | - | |
| Bali Muralidhar | M | 44 | 2 years | |
| Thomas Grimaud | M | 46 |
Vivalis SA
Vivalis SA Pharmaceuticals: OtherHealth Technology Vivalis SA manufactures human and animal vaccines. The firm specializes in the research and development of vaccines and antiviral molecules, as well as in recombinant therapeutic protein and monoclonal antibody expression systems development. The firm's embryonic stem cells are used for practical applications in human and animal health. It also helps its clients in a case by case basis for the development of processes in the frame of service agreement. The company was founded in April 1999 and is headquartered in France. | 11 years |
| Pierre Miniou | M | - |
Vivalis SA
Vivalis SA Pharmaceuticals: OtherHealth Technology Vivalis SA manufactures human and animal vaccines. The firm specializes in the research and development of vaccines and antiviral molecules, as well as in recombinant therapeutic protein and monoclonal antibody expression systems development. The firm's embryonic stem cells are used for practical applications in human and animal health. It also helps its clients in a case by case basis for the development of processes in the frame of service agreement. The company was founded in April 1999 and is headquartered in France. | 10 years |
| Stephen Brown | M | - |
Vivalis SA
Vivalis SA Pharmaceuticals: OtherHealth Technology Vivalis SA manufactures human and animal vaccines. The firm specializes in the research and development of vaccines and antiviral molecules, as well as in recombinant therapeutic protein and monoclonal antibody expression systems development. The firm's embryonic stem cells are used for practical applications in human and animal health. It also helps its clients in a case by case basis for the development of processes in the frame of service agreement. The company was founded in April 1999 and is headquartered in France. | 9 years |
| David Lawrence | M | 61 | - | |
| Anne-Sophie Herelle | F | 43 | - | |
| Reinhard Kandera | M | 54 | 4 years | |
| Joseph Grimaud | M | 83 |
Vivalis SA
Vivalis SA Pharmaceuticals: OtherHealth Technology Vivalis SA manufactures human and animal vaccines. The firm specializes in the research and development of vaccines and antiviral molecules, as well as in recombinant therapeutic protein and monoclonal antibody expression systems development. The firm's embryonic stem cells are used for practical applications in human and animal health. It also helps its clients in a case by case basis for the development of processes in the frame of service agreement. The company was founded in April 1999 and is headquartered in France. | 7 years |
| Thomas Casdagli | M | 47 | 2 years | |
| Klaus Schwamborn | M | - | 9 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| France | 43 | 95.56% |
| Austria | 3 | 6.67% |
| China | 1 | 2.22% |
| United States | 1 | 2.22% |
| Mexico | 1 | 2.22% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Frédéric Grimaud
- Personal Network
